Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Dr Francois Nader – NPS Pharmaceuticals – Executive Leadership Series

Authored by Karl Simpson

At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Francois Nader performed for NPS Pharmaceuticals in 2013.

2013 Liftstream Analysis: Francois Nader’s NPS Pharma crept up on everyone last year and by the year end, they were sitting with an FDA approval tucked safely away in their back pockets and were planning for a launch of Gattex.  With a planned submission for Natpara in Q2/3 2013, the company has a real shot at being a 3 product company in short order. Given they already have a commercial tie up with Amgen for Sensipar and now Takeda in Europe for Gattex, the company is facing two primary challenges as we see it; Commercial success for Gattex with an effective pricing and reimbursement strategy. Also, maintaining independence. With a current market Cap of $800m, they are potentially in the cross hairs for those companies looking for interesting acquisitions in the orphan drug market.

• Commercial launch of Gattex

• Regulatory approval of Naptara

• Remaining independent, assuming this is what they want

2014 Liftstream Verdict: 2013 was a hot year for rare disease companies. One of the strongest of the companies to emerge last year was NPS Pharmaceuticals. Dr. Nader firstly oversaw a commercial launch of Gattex in the US and the launch is underway here in Europe too, having re-acquired the rights from Takeda. Naptara’s BLA has been submitted to the FDA and is on course for European review by the EMA. This will continue to build revenue top-line growth for the company. The company went public in 2013 and this provided access to capital to enable independent commercialisation. With a value of $3bn and three marketed products in the offering, NPS is now a very real acquisition target.

To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email or tweet @liftstream #LSL13for13

Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector. 

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , | Leave a comment

Contact Us

   Head Office
Liftstream Ltd.
111 Buckingham Palace Road,
   Tel: ​+44 (0)20 3180 5880

Register your CV

Apply for sector specific vacancies or request a confidential discussion

Registered in England No: 5009233
VAT: 843679292

Follow Us